<DOC>
	<DOCNO>NCT01173510</DOCNO>
	<brief_summary>Human Immunodeficiency Virus ( HIV ) infection permanently establish integrate deoxyribonucleic acid ( DNA ) copy human chromosome , step also necessary complete Human Immunodeficiency Virus ( HIV ) replication cycle . Standard treatment HIV infection suppress Human Immunodeficiency Virus ( HIV ) replication able eliminate Human Immunodeficiency Virus ( HIV ) infect person integrate Human Immunodeficiency Virus ( HIV ) . Raltegravir ( RAL ) , first approve antiretroviral ( ARV ) new class call integrase inhibitor , work prevent integration Human Immunodeficiency Virus ( HIV ) . For participant Human Immunodeficiency Virus ( HIV ) never take antiretroviral medication , research study test whether Raltegravir ( RAL ) , recommend first-line ARV , eliminate Human Immunodeficiency Virus ( HIV ) key immune system cell .</brief_summary>
	<brief_title>A Pilot Study Determine Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells</brief_title>
	<detailed_description>This phase IV study compare RAL EFV ability clear HIV mononuclear cell . Participants randomize 2:1 either RAL plus co-formulated FTC/TDF EFV/FTC/TDF ( Atripla ) . The study last minimum 24 week . Participants come three day week 4 24 visit receive subcutaneous injection G-CSF , FDA-approved medication mobilize certain cell . A minimum 5 visit require baseline blood draw , safety monitoring , G-CSF injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Male female subject age 18 old HIV1 infection CD4 cell count great 200 cells/mm screen Plasma HIV RNA &gt; 1000 copies/mL Women childbearing potential must use adequate method contraception avoid pregnancy throughout study eight week last dose study drug . Women childbearing potential include woman experience menarche undergone successful surgical sterilization postmenopausal . Previous exposure antiretroviral medication use treatment HIV1 infection Evidence genotypic phenotypic resistance medication use study ( tenofovir , emtricitabine , efavirenz ) resistance assay obtain patient 's primary care physicians standard care test Women positive pregnancy test , pregnant , breast feeding Sexually active nonsterilized men use effective birth control female partner childbearing potential Women childbearing potential unwilling unable use acceptable method avoid pregnancy entire study period eight week last dose study drug Presence currently active AIDSdefining category C condition accord CDC Classification System HIV Infection exception stable cutaneous Kaposi 's sarcoma Any active , clinically significant disease opinion Principal Investigator may compromise subject 's safety trial Grade 3 4 Laboratory abnormality define standardized grade scheme base DAIDS table ACTG Toxicity Grading Scale elevation ( except preexist diabetes mellitus asymptomatic , nonfasting glucose grade 3 elevation , asymptomatic â‰¥ grade 3 fast triglyceride cholesterol elevation , subject elevate indirect bilirubin ) Active substance abuse significant psychiatric illness opinion Principal Investigator may interfere study compliance Prisoners subject involuntarily incarcerate Subjects compulsorily detain treatment either psychiatric physical ( e.g . infectious disease ) illness Known hypersensitivity GCSF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Atripla</keyword>
	<keyword>Truvada</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
</DOC>